How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.

CONCLUSIONS: Evaluation of a lipoprotein landscape when LDL-C levels remain low strongly supports the role of non-HDL-C, Lp(a) and TGs in identifying patients with increased residual risk of CV and in selecting their treatment strategy. PMID: 28434480 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/28434480?dopt=Abstract

Source: Atherosclerosis Supplements - April 1, 2017 Category: Cardiology Authors: Averna M, Stroes E, lipid alterations beyond LDL expert working group Tags: Atheroscler Suppl Source Type: research